Qing Yi, MB, PhD

Publications

195

4 grants

PI
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy
NCI · 2024–2029 · via NIH RePORTER
R01CA285203-03
PI
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
NCI · 2024–2028 · via NIH RePORTER
R01CA285209-03
PI
Role of lipid metabolism in CD8+ T cell ferroptosis
NCI · 2023–2028 · via NIH RePORTER
R01CA278787-04
PI
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells
NCI · 2023–2028 · via NIH RePORTER
R01CA282099-04

Completed grants (11)

PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion
NCI · 2019–2025 · via NIH RePORTER
R01CA239255-05
PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
NCI · 2017–2023 · via NIH RePORTER
R01CA214811-05
PI
Role of MIF in myeloma bone homing and drug response
NCI · 2017–2022 · via NIH RePORTER
R01CA211073-05
PI
A novel T-cell subset able to kill relapsed cancers
NCI · 2016–2022 · via NIH RePORTER
R01CA200539-06
PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA
NCI · 2010–2018 · via NIH RePORTER
P50CA142509-05
PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma
NCI · 2012–2018 · via NIH RePORTER
R01CA163881-06
PI
Mechanisms of Processivity in Molecular Motors
NIGMS · 2002–2017 · via NIH RePORTER
R01GM102875-10
PI
C-reactive protein promotes myeloma cell-mediated bone destruction
NCI · 2010–2016 · via NIH RePORTER
R01CA138398-06
PI
Targeting surface b2M for myeloma and bone therapy
NCI · 2009–2014 · via NIH RePORTER
R01CA138402-04
PI
Optimizing Dendritic Cell Immunotherapy in Myeloma
NCI · 2004–2010 · via NIH RePORTER
R01CA103978-06
PI
Idiotype-specific effector T cells in multiple myeloma
NCI · 2002–2008 · via NIH RePORTER
R01CA096569-06